Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)

Wiwanitkit, Viroj

doi:10.2147/tcrm.s30139

Cited by 59 publications

(41 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…aspiculamyceticus [112] . The antileishmaniasis aminoglycoside (10) under the common name of paromomycin, was first reported from a Streptomyces species [113] and to date, appears on the WHO essential 20 th list of medicines [23] . Previous work by Ser et al detected compound (5) in Streptomyces extract of with potent antioxidant and anticancer activity [41] .…”

Section: Discussionmentioning

confidence: 99%

Investigating the antioxidant potential of Streptomyces sp. MUSC 11 from mangrove soil in Malaysia

Kemung¹,

Tan²,

Chan³

et al. 2019

Prog Drug Discov Biomed Sci

View full text Add to dashboard Cite

Streptomyces are a distinguished group of gram-positive bacteria mostly acknowledged for their immense contribution to life-saving drugs and lines of compounds with diverse bioactivities. To date, there remains limited studies on Streptomyces with biological activities residing in underexplored ecosystems such as the mangrove forests. For this purpose, the present work aimed at investigating the biological activity of Streptomyces sp. MUSC 11 collected from soil sample in mangrove forests, situated in the State of Pahang, Peninsular of Malaysia. The cultured strain resembled phenotypic and genotypic traits of genus Streptomyces. Investigations of the methanolic extract from Streptomyces sp. MUSC 11 revealed antioxidant activities in form of scavenging free radicals ABTS, DPPH, chelating iron and reducing ferric iron. Besides the antioxidant tests, antioxidant results corresponded well to the presence of phenolic content. In summary, Streptomyces derived from extreme and understudied ecosystem such as the mangrove forests are potential sources of biologically active and therapeutically useful compounds.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigating the antioxidant potential of Streptomyces sp. MUSC 11 from mangrove soil in Malaysia

Kemung¹,

Tan²,

Chan³

et al. 2019

Prog Drug Discov Biomed Sci

View full text Add to dashboard Cite

show abstract

“…However, the issue associated with miltefosine is that it cannot be used in pregnant and feeding women because it can harm the developing fetus in the womb [42]. A new drug, Humatin has been developed recently with similar efficiency as AmB but with a limited number of side effects [43].…”

Section: Conventional Treatment Strategies Against Leishmaniasis and mentioning

confidence: 99%

Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

et al. 2019

View full text Add to dashboard Cite

Leishmaniasis is a widely distributed protozoan vector-born disease affecting almost 350 million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but they had toxic side effects. Various nanotechnology-based techniques and products have emerged as anti-leishmanial drugs, including liposomes, lipid nano-capsules, metal and metallic oxide nanoparticles, polymeric nanoparticles, nanotubes and nanovaccines, due to their unique properties, such as bioavailability, lowered toxicity, targeted drug delivery, and biodegradability. Many new studies have emerged with nanoparticles serving as promising therapeutic agent for anti-leishmanial disease treatment. Liposomal Amphotericin B (AmB) is one of the successful nano-based drugs with high efficacy and negligible toxicity. A new nanovaccine concept has been studied as a carrier for targeted delivery. This review discusses different nanotechnology-based techniques, materials, and their efficacies in leishmaniasis treatment and their futuristic improvements.

show abstract

“…Due to its limited use resistance is not yet recorded in patient treatment but reported in vitro in L. tropica and L. donovani (Jhingran et al 2009). To overcome these problems PM is being reported in combination with liposome and albumin microsphere and thereby exhibiting better results (Wiwanitkit, 2012).…”

Section: Paromomycinmentioning

confidence: 99%

Slow pace of antileishmanial drug development

Kumar¹,

Pandey

Samant

2018

Parasitology Open

View full text Add to dashboard Cite

The protozoan parasiteLeishmaniais endemic in large parts of the world which causes leishmaniasis. Its visceral form is fatal if not treated and is caused mostly byLeishmania donovani,Leishmania infantumandLeishmania chagasi. Given the difficulties linked to vector (sandfly) control and the lack of an effective vaccine, the control of leishmaniasis relies mostly on chemotherapy. Unfortunately, the prevalence of parasites becoming resistant to the first-line drug pentavalent antimony (SbV) is increasing worldwide. Few alternative drugs are available that includes amphotericin B, pentamidine and miltefosine (oral). Already, decreases in efficacy, resistance and toxicity have been noted against these drugs. Dry antileishmanial pipeline further indicates the slow pace of drug discovery in this field where resistance as a major barrier. Full understanding of the genetic and molecular basis of the parasite is lagging. Since leishmaniasis is a neglected disease and occurs predominantly in the developing world largely, therefore, it is unaddressed. The pharma industry argues that development of the new drug is too costly and risky to invest in low return neglected diseases is very high. Research is also needed to identify new and effective drug targets. The lack of drug research and development for neglected diseases will require some new strategies. We have discussed the various cause of slow pace of antileishmanial drug discovery in this review to pay attention of researchers and also take the public and private initiative to make the process fast for new antileishmanial drug development.

show abstract

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)

Cited by 59 publications

References 47 publications

Investigating the antioxidant potential of Streptomyces sp. MUSC 11 from mangrove soil in Malaysia

Investigating the antioxidant potential of Streptomyces sp. MUSC 11 from mangrove soil in Malaysia

Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

Slow pace of antileishmanial drug development

Contact Info

Product

Resources

About